Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

aTyr Pharma, Inc. - Common Stock (NQ:LIFE)

1.900 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about aTyr Pharma, Inc. - Common Stock

News headline image
Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution
From Ethos Technologies Inc
Via GlobeNewswire
News headline image
Ethos Files Registration Statement for Proposed Initial Public Offering
From Ethos Technologies Inc
Via GlobeNewswire
News headline image
Ethos and Lifeforce Team Up to Help Policyholders Live Longer, Healthier Lives
New benefit gives Ethos policyholders access to Lifeforce’s comprehensive health optimization platform, including biomarker testing, evidence-based longevity protocols, and expert health coaching 
From Ethos Technologies Inc
Via GlobeNewswire
News headline image
Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors
Former President of Athene brings decades of insurance, retirement, and financial services leadership to support Ethos’ next stage of growth 
From Ethos Technologies Inc
Via GlobeNewswire
News headline image
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
Ticker symbol change to take effect on Wednesday, June 5, 2024 
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
Findings further demonstrate that NRP2 is an important new immune target in ILD and that efzofitimod modulates myeloid cells to confer anti-inflammatory benefit 
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma to Present at Upcoming Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma to Participate in April Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT 
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
Dr. Frederick to advise Company on corporate affairs and commercial strategy for efzofitimod in interstitial lung disease (ILD). 
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
Beat of Life Entertainment's 'Diya Jalao Roshni Lao' Campaign: Lighting Up Lives and Preserving Tradition!
The "Diya Jalao Roshni Lao" campaign was initiated by the Beat of Life Entertainment company in 2022. Its aim is to draw people's attention to our culture, the hard work of potters, hope, their lives,... 
Via IssueWire
Topics Religion
News headline image
aTyr Pharma to Present at November Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
Multiple centers in the U.S. are open for enrollment 
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
From aTyr Pharma, Inc.
Via GlobeNewswire
News headline image
Beat Of Life Entertainment- A One Stop Solution For Internet Marketing
Internet marketing is the solution for business development in the digitalization era. 
Via IssueWire
Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&D
Via FinancialNewsMedia
Topics Death
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.